文献速递肿瘤 PET/CT

优化肝内胆管癌分期:[18F]FDG、[68Ga]Ga-FAPI与[68Ga]Ga-Trivehexin PET/CT显像比较

Optimizing Intrahepatic Cholangiocarcinoma Staging: Comparison of [ 18 F]FDG, [ 68 Ga]Ga-FAPI, and [ 68 Ga]Ga-Trivehexin PET/CT Imaging.
PubMed 文献 · Clin Nucl Med · 2026-01-20

本文报道一例肝内胆管癌患者初始分期中分别接受[18F]FDG、[68Ga]Ga-Trivehexin与[68Ga]Ga-FAPI-04 PET/CT检查。原发肝病灶在三种示踪剂中均呈递进性摄取增高;转移性颈部淋巴结可被[68Ga]Ga-FAPI-04与[68Ga]Ga-Trivehexin显示而[18F]FDG未显示;[68Ga]Ga-FAPI-04还可显示转移性腹部淋巴结。提示[68Ga]Ga-Trivehexin PET/CT或可替代[18F]FDG PET/CT,而FAPI对两者均构成有力竞争。

要点

  • 原发肝病灶在[18F]FDG、[68Ga]Ga-Trivehexin与[68Ga]Ga-FAPI-04 PET/CT中均呈递进性摄取增高。
  • 转移性颈部淋巴结可被[68Ga]Ga-FAPI-04与[68Ga]Ga-Trivehexin显示,而[18F]FDG未显示。
  • [68Ga]Ga-FAPI-04 PET/CT还可显示转移性腹部淋巴结。

核心结论

  • 本病例提示[68Ga]Ga-Trivehexin PET/CT可能作为[18F]FDG PET/CT的替代方案,值得重新评估FDG的局限性,而FAPI对两者均构成有力竞争。

研究设计与样本

  • 本文为单例肝内胆管癌患者的病例报道,患者在初始分期中接受了[18F]FDG、[68Ga]Ga-Trivehexin与[68Ga]Ga-FAPI-04 PET/CT三种显像。

主要发现

  • 原发肝病灶在三种示踪剂中均表现为递进性摄取增高。
  • 转移性颈部淋巴结在[68Ga]Ga-FAPI-04 PET/CT与[68Ga]Ga-Trivehexin PET/CT中可显示,而[18F]FDG PET/CT未显示。
  • [68Ga]Ga-FAPI-04 PET/CT额外显示了转移性腹部淋巴结。

临床怎么用

  • 对于肝内胆管癌初始分期,可考虑[68Ga]Ga-Trivehexin PET/CT作为[18F]FDG PET/CT的替代选择,同时[68Ga]Ga-FAPI-04 PET/CT在淋巴结转移显示方面具有竞争力。

局限性

  • 本文为单例病例报道,结论需在更大样本中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herein, we present a case of a patient with intrahepatic cholangiocarcinoma (ICC) who underwent [ 18 F]FDG, [ 68 Ga]Ga-Trivehexin, and [ 68 Ga]Ga-FAPI-04 PET/CT scans for initial staging. The primary liver lesion demonstrates progressively increased uptake across all 3 tracers, whereas metastatic cervical lymph nodes are visualized with [ 68 Ga]Ga-FAPI-04 PET/CT and [ 68 Ga]Ga-Trivehexin but not with [ 18 F]FDG; importantly, [ 68 Ga]Ga-FAPI-04 PET/CT, in addition, delineates metastatic abdominal lymph nodes. This case highlights that [ 68 Ga]Ga-Trivehexin PET/CT may serve as an alternative to [ 18 F]FDG PET/CT, warranting reevaluation of FDG limitations, while FAPI remains a strong competitor to both.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Denizmen Zorba D, Arslan DF, Sanli Y, et al. Optimizing Intrahepatic Cholangiocarcinoma Staging: Comparison of [ 18 F]FDG, [ 68 Ga]Ga-FAPI, and [ 68 Ga]Ga-Trivehexin PET/CT Imaging. Clin Nucl Med. 2026. PMID: 41627164. doi:10.1097/RLU.0000000000006310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。